Drug intelligence / Profile preview

DiR-Metabolic

Development stage: Preclinical
Lead developer: Aptadir Therapeutics
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

DiR-Metabolic is a preclinical-stage RNA therapeutic being developed by Aptadir Therapeutics for the treatment of undisclosed metabolic disorders. The drug utilizes a novel modality known as DNMT1-interacting RNA (DiR). The mechanism of action involves the DiR RNA molecule interacting with and inhibiting DNA methyltransferase 1 (DNMT1). This interaction is designed to prevent aberrant DNA methylation in a locus-specific manner, thereby modulating gene expression associated with metabolic pathology.

Other names: DNMT1-interacting RNA for metabolic disordersDNMT-1-interacting RNA for metabolic disordersDNMT 1-interacting RNA for metabolic disorders

Targets

DNMT1 (DNA (cytosine-5)-methyltransferase 1)

Beyond the preview

Go deeper on DiR-Metabolic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiR-Metabolic.

Explore the full profile